# Follow-up of NAFLD Patients With MRI-PDFF

> **NCT04910178** · PHASE4 · COMPLETED · sponsor: **Asmaa Abdelfattah Elsayed** · enrollment: 80 (actual)

## Conditions studied

- Diabetes Type 2
- NAFLD

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Ursodeoxycholic acid
- **DRUG:** Pentoxifylline 400 MG
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04910178
- **Lead sponsor:** Asmaa Abdelfattah Elsayed
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910178, "Follow-up of NAFLD Patients With MRI-PDFF". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04910178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*